Business
Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours
Strong preclinical data support planned clinical trial initiation in 2026 Oslo, Norway, 16 December 2025– Zelluna (OSE: ZLNA), a company developing off-the-shelf cell therapies for cancer, today announced the publication of preclinical data for its lead candidate, ZI-MA4-1, in the peer-reviewed journal Immunotherapy Advances*. The data support the company's plan to start clinical trials in 2026. The paper describes ZI-MA4-1, a novel cell therapy that combines two powerful cancer-fighting mechani
About this update from Zelluna Asa
[{"type":"image","alt":"Zelluna ASA","displaySize":"","headline":null,"caption":"Zelluna ASA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":106,"url":"https://media.zenfs.com/en/globenewswire.com/a3f855525ffb13acd9e8579786771e69"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C3Qdgv86SfCXtr_6x5fSRg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a3f855525ffb13acd9e8579786771e69","width":300,"height":106}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Strong preclinical data support planned clinical trial initiation in 2026","length":73,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":73,"olType":false},{"type":"text","content":"Oslo, Norway, 16 December 2025– Zelluna (OSE: ZLNA), a company developing off-the-shelf cell therapies for cancer, today announced the publication of preclinical data for its lead candidate, ZI-MA4-1, in the peer-reviewed journal Immunotherapy Advances*. The data support the company's plan to start clinical trials in 2026.","length":333,"tagName":"p"},{"type":"text","content":"The paper describes ZI-MA4-1, a novel cell therapy that combines two powerful cancer-fighting mechanisms: the precision solid tumour targeting of T cell receptors (TCRs) with the potent and broad cancer killing ability of Natural Killer (NK) cells. ZI-MA4-1 targets MAGE-A4, a protein found in many solid cancers including lung, ovarian, head and neck, and sarcomas.","length":366,"tagName":"p"},{"type":"text","content":"Key results:","length":12,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Kills cancer cells effectively across multiple tumour types","length":64,"tagName":"p"}]},{"val":[{"type":"text","content":"Works even when tumours try to hide – remains active despite common escape mechanisms","length":90,"tagName":"p"}]},{"val":[{"type":"text","content":"Enhanced immune response – triggers multiple anti-cancer mechanisms","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"Good safety profile in preclinical studies","length":47,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":273,"olType":false},{"type":"text","content":"Since ZI-MA4-1 is manufactured in advance and stored frozen, it can be given to patients on demand (off-the-shelf), enabling multi...